For the Inventor, By the Inventor

Enter assignee name

Vancouver, Canada

Zymeworks Inc.

USPTO Granted Patents = 56

% Expired Patents = 7.1

CIPO Patents = 4

EPO Patents = 21

Trademarks = 6

Forward Citations = 334

Loading Chart...

Loading Chart...

70 inventors (with patents filed for the assignee):

Surjit Bhimarao Dixit (27 out of 27 patents)

Thomas Spreter Von Kreudenstein (14 out of 18 patents)

Paula Irene Lario (13 out of 15 patents)

4. Gordon Yiu Kon Ng (12 out of 15 patents)

5. Mario Sanches (12 out of 18 patents)

6. Eric Escobar-Cabrera (11 out of 14 patents)

7. James R Rich (10 out of 16 patents)

8. Igor Edmondo Paolo D'Angelo (9 out of 10 patents)

9. Stacey A L Tom-Yew (7 out of 10 patents)

10. Tom Han Hsiao Hsieh (7 out of 13 patents)

11. David Kai Yuen Poon (7 out of 7 patents)

12. Geoffrey C Winters (7 out of 14 patents)

13. Alexander Laurence Mandel (7 out of 12 patents)

14. Dunja Urosev (6 out of 12 patents)

15. Adam Louis Corper (6 out of 9 patents)

Core Competencies:

Bispecific Antibodies

Drug Conjugates

Multivalent Constructs

Antigen-Binding Polypeptides

Immunoglobulin Pairs

Cytotoxic Compounds

Polymer Dynamics

Heteromultimers

Protein Design

Fc Domain Mutations

Checkpoint Inhibitors

Cancer Treatment

56 patents: Sort by Forward Citations

1. 11560422 - Sulfonamide-containing linkage systems for drug conjugates (2023-01-24),

2. 11351251 - Anti-PD-L1-anti-TIM-3 bispecific antibodies (2022-06-07),

3. 11325981 - Bispecific antigen-binding constructs targeting Her2 (2022-05-10),

4. 11306156 - Modified antigen binding polypeptide constructs and uses thereof (2022-04-19),

5. 11286293 - Engineered immunoglobulin heavy chain-light chain pairs and uses thereof (2022-03-29),

6. 11248037 - Multivalent heteromultimer scaffold design and constructs (2022-02-15),

7. 11208497 - Antibodies comprising C-terminal light chain polypeptide extensions and conjugates and methods of use thereof (2021-12-28),

8. 11203640 - Checkpoint inhibitor bispecific antibodies (2021-12-21),

9. 11161915 - Antigen-binding polypeptide constructs comprising kappa and lambda light chains and uses thereof (2021-11-02),

10. 11152081 - Methods for determining correlated residues in a protein or other biopolymer using molecular dynamics (2021-10-19),

11. 11147886 - Drug-conjugated bi-specific antigen-binding constructs (2021-10-19),

12. 11098105 - Heteromultimers with reduced or silenced effector function (2021-08-24),

13. 11078296 - Engineered immunoglobulin heavy chain-light chain pairs and uses thereof (2021-08-03),

14. 11072658 - Anti-PD-1/LAG3 bispecific antibodies (2021-07-27),

15. 11031093 - Systems and methods for identifying thermodynamically relevant polymer conformations (2021-06-08),

Zymeworks Inc., headquartered in Vancouver, Canada, specializes in the development of innovative biopharmaceuticals, particularly focusing on bispecific antibodies and drug conjugates. The company leverages its expertise in multivalent constructs and antigen-binding polypeptides to create advanced therapeutic solutions. Zymeworks is dedicated to addressing unmet medical needs through its cutting-edge technologies, including immunoglobulin pairs and cytotoxic compounds, while also exploring polymer dynamics and heteromultimers to enhance drug efficacy.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

56 Patents

#14 in Vancouver

#246 in Canada

#12,732 in the World

Vancouver, Canada

Zymeworks Inc.

Forward Citations = 334

70 inventors:

Surjit Bhimarao Dixit (27 out of 27 patents)

Thomas Spreter Von Kreudenstein (14 out of 18 patents)

Paula Irene Lario (13 out of 15 patents)

4. Gordon Yiu Kon Ng (12 out of 15 patents)

5. Mario Sanches (12 out of 18 patents)

Please report any incorrect information to [email protected]

Loading…